A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 737 participants.
Also called NCT01644500
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 737 participants
- Sponsor
- Registry
-
NCT01644500
-
- Other papers using this trial's data
- A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, South Korea, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT01644500. Randomized; triple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2015-12-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus
- Acronym
- AWARD-CHN1
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Dulaglutide
- Intervention (Drug)
- Glimepiride
- Intervention (Drug)
- Placebo as Capsules
- Intervention (Drug)
- Placebo as SC Injection
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01644500- Content hash
ff3e11d8d85aa27f5bb231f7882b5f581363d997b407ed92b828c883be7fa7d5